Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA®. Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the U.S. and Europe indicating that the samples contain LNPs falling under the protective scope of the claims of their lipid composition patents.
The cases are:
Canada: Federal Court of Canada File No. T-704-25, seeking a permanent injunction and damages or, if Genevant so elects, an accounting of Moderna's profits, attributable to infringement of Canadian Patent No. 2,721,333.
Japan: Tokyo District Court Case No. 2025 (Wa) 70079, seeking a permanent injunction and reasonable royalty for infringement of Japanese Patent No. 5,475,753.
Switzerland: filing a case seeking a permanent injunction and monetary relief, which upon later choice of Genevant and Arbutus can include surrender of profits, damages or a reasonable royalty, for infringement of EP 2 279 254.
Unified Patent Court (UPC): Case 10280/2025, seeking permanent and provisional injunctions, as well as monetary damages, which can include recovery of Moderna's unfair profits, from infringement of EP 2 279 254.
UPC: Case 10284/2025, seeking permanent and provisional injunctions, as well as monetary damages, which can include recovery of Moderna's unfair profits, from infringement of EP 4 241 767.
The UPC actions together seek relief for: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland/Liechtenstein, and Turkey.
Today's actions expand on Arbutus and Genevant's ongoing enforcement proceeding in the U.S. District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six U.S. patents in the manufacture and sale of Spikevax®. A jury trial is currently scheduled for September 2025.
It is well established in the scientific literature that the most significant technological hurdle to developing and deploying medicines using mRNA is engineering a safe and effective way to deliver the mRNA to human cells. Scientists at Arbutus and Genevant have spent years developing and refining LNP delivery technology, which has been licensed for various applications to many different third parties, including Moderna. Arbutus and Genevant's LNP technology relies on microscopic particles built from four carefully selected types of fat-like molecules to shelter and protect mRNA molecules and to enable them to travel through the human body to a target cell and through the target cell's membrane before releasing the mRNA. Without this crucial delivery technology, mRNA would quickly degrade in the body and be ineffective.
About Genevant Sciences
Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, a robust lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. Genevant's scientists have pioneered LNP delivery of nucleic acids for over 20 years, and Genevant's LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit www.genevant.com.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The company is currently developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV). Through its ownership stake in and license agreement with Genevant, Arbutus is also focused on maximizing opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include, but are not limited to, statements about: Arbutus' plans with respect to the ongoing patent litigation matters.
Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
CONTACT: Contact: Pete Zorn pete.zorn@genevant.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Why AI Robotics Stock Symbotic Surged 38.9% in July
Key Points More analysts are turning bullish on Symbotic after its Walmart deal. The stock has more than doubled in just six months. Symbotic shares could cool off a bit from here, but there's nothing to worry about. 10 stocks we like better than Symbotic › Symbotic (NASDAQ: SYM) stock has gone ballistic. A stunning rally of 38.9% in July drove the stock's half-yearly performance to a staggering 127.5%, according to data provided by S&P Global Market Intelligence. On Aug. 5, Symbotic hit a 52-week high of $64.16 per share. Symbotic automates warehouses and distribution centers with its artificial intelligence (AI)-powered robots and software. Symbotic's deal with Walmart (NYSE: WMT), in particular, has spurred massive investor interest in its stock, with several analysts upgrading their price targets in recent weeks. Why are analysts turning bullish on Symbotic stock? Analysts from Citi, Arete, Northland, and Oppenheimer were among those that initiated coverage or upgraded their price targets on Symbotic stock in July. While Arete has a price target of $50 per share on Symbotic, analysts from Northland raised their price target on the AI stock to $56 per share from $35 a share. Citi analyst Andrew Kaplowitz upped the stock's price target to $60 from $29 per share. Oppenheimer analyst Colin Rusch, meanwhile, raised Symbotic's price target from $35 per share to $54 a share in July, and then by another $5 in early August. In January, Symbotic acquired Walmart's advanced systems and robotics (ASR) business and signed a commercial agreement with the retail giant to deploy robotics automation systems for up to 400 accelerated pickup and delivery (APD) centers at Walmart stores over the next few years. Symbotic estimates incremental backlog of $5 billion from the deal. As news of Walmart testing "dark stores" to fulfill online orders hit the headlines in late June and through July, investors analysts bumped up their expectations from Symbotic stock and drove its price higher. Shares hit a new 52-week high of $64.16 ahead of earnings on Aug. 5. Could Symbotic stock lose momentum from here? Symbotic beat estimates with 26% year-over-year growth in revenue for its third quarter. Its net loss, however, widened to $32 million from $21 million a year ago because of restructuring charges. Moreover, the company's Q4 revenue guidance of $590 million to $610 million would mean only 4% year-over-year growth at the midpoint. Investors don't want to see a deceleration in sales from a growth stock that's yet to turn profitable. Yet investors should also look beyond the headlines. Symbotic is ready to deploy a next-generation storage system at warehouses that should significantly improve storage capacity and handling. The company, however, is facing startup problems, but expects them to be a temporary blip. Management insisted that none of it affects the company's backlog, which stands at a solid $22.4 billion today. To put that number into perspective, Symbotic generated revenue worth $1.8 billion last year. Long story short, Symbotic could face some quarters of slow revenue growth, but that shouldn't hurt the long-term growth potential of this AI and robotics stock. Should you invest $1,000 in Symbotic right now? Before you buy stock in Symbotic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Symbotic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Citigroup is an advertising partner of Motley Fool Money. Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Symbotic and Walmart. The Motley Fool has a disclosure policy. Why AI Robotics Stock Symbotic Surged 38.9% in July was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Trade Desk shares drop on report of Walmart advertising deal change
-- The Trade Desk (NASDAQ:TTD) saw its shares drop 6% Thursday after The Information reported that Walmart Inc (NYSE:WMT) modified its advertising partnership, potentially opening the retail giant's shopper data to rival platforms. The reported changes mark a shift from a four-year exclusivity clause that funneled advertisers toward The Trade Desk's technology. People familiar with the matter told The Information that Walmart removed the requirement for advertisers accessing its shopper data to use The Trade Desk's tools. The non-exclusive arrangement could diminish The Trade Desk's competitive edge in a sector where scale and first-party data are critical. The move comes during an especially turbulent period for the Ventura, Calif.-based ad-tech firm. Shares plunged 35% last Friday after it forecast slower third-quarter revenue growth, following a second-quarter slowdown. CEO Jeff Green attributed part of the weakness to 'ongoing tariff uncertainty' putting pressure on large advertisers. The company's stock has dropped about 50% over the past year, reflecting investor unease over near-term growth prospects. Losing exclusivity with Walmart threatens a partnership in one of the most valuable retail media ecosystems. The Trade Desk has relied on its automated ad-buying expertise, particularly in streaming TV, to position itself against advertising titans like Amazon and Google. Amazon has been courting marketers aggressively, reportedly offering incentives to draw clients from The Trade Desk. In digital advertising, such data-driven relationships are seen as central to revenue growth and margin expansion. In a statement responding to the reports, The Trade Desk pushed back on suggestions of a fracture in the collaboration. The company said its 'partnership' with Walmart 'has gone from strength to strength…[and] continues to expand.' Markets will be watching whether competitors can exploit Walmart's strategic flexibility to erode The Trade Desk's position. For now, the combination of weaker guidance, macro headwinds, and loosening retailer ties has left the stock near its lowest of the year. Related articles Trade Desk shares drop on report of Walmart advertising deal change What happens to stocks if AI loses momentum? Can a rally in EM financial markets extend?
Yahoo
an hour ago
- Yahoo
July PPI/Core PPI Jumped Unexpectedly
Major economic data is out this morning, and it's having an impact on trading futures. Inflation metrics and employment tallies — both sides of the Fed's dual mandate — were represented. As a result, the Dow moved from +3 points directly ahead of the releases to -180 points currently, the S&P 500 went from -1 point to -30 points and the Nasdaq slid from +7 to -140. The small-cap Russell 2000 has already given up most of its gains from yesterday, -36 points. Producer Price Index (PPI) Jumps 90 Basis Points in a Month Headline PPI — the wholesale side of inflation, as opposed to the retail print Consumer Price Index (CPI) out Tuesday morning — jumped from 0.0% a month ago to +0.9% today, reporting for the month of July. Stripping out volatile food and energy costs, we're still up 90 basis points (bps) on core PPI month over month. Ex-food, energy and trade, we have tripled expectations to +0.6%. These are now at the hottest levels since over year is a slightly different story, as early in the year they were still over +3%. July's headline PPI came in at +3.3% — the highest since February, but also up 90 bps from an upwardly revised +2.4% for June. Core PPI year over year soared +1.1% in one month to +3.7% — the highest level since March. Ex-food, energy and trade rose just 30 bps month over month to +2.8%.To the extent producer prices lead into consumer prices — not completely, but undeniably part of the economic chain — we might expect higher CPI data as of the September print, which hits the tape roughly a week ahead of the next Fed meeting on interest rate policy. Depending on how high those results become may put the rate-cut being priced into the market currently in jeopardy. At very least, I don't hear much about a pending 50-bps cut following this PPI report. Jobless Claims Remain Range-Bound: 224K, 1.95M Weekly Jobless Claims are also out this morning, being a normal Thursday. Initial Claims dipped -3K to 224K week over week, now sub-230K for 6 straight weeks. (Remember the first week of June was 250K with an upward arrow, but these numbers have methodically diminished since.) Recent lows were +219K four weeks Claims notched its 12-straight week above 1.9 million without tipping into the psychologically relevant 2 million longer-term weekly jobless claims. A headline of 1.953 million is down -15K from the downwardly revised 1.968 million the prior week — which, incidentally, is still the highest level we've seen since November 2021. From mid-April through late May, weekly longer-term claims rose +120K. But they have remained frozen just below 2 million since. For some perspective, we spent even a longer time in the 1.8 million range of continuing jobless claims — from late summer 2024 to early spring this year. Also, longer-term claims do have an expiration date, though this is not a straight number across all circumstances. Earnings Reports Ahead of the Open Heavy machinery manufacturer Deere & Co. DE posted fiscal Q3 results this morning, outperforming on both top and bottom lines: earnings of $4.75 per share beat the Zacks consensus by +7.8%, while revenues of $10.36 billion outpaced expectations by +1% ahead of the bell. Yet full-year guidance was a little softer than investors were looking for, and shares are selling off -6% on the news. For more on DE's earnings, click here.A bevy of publicly-traded Chinese firms are also out with earnings results this morning. JD posted earnings of 69 cents per share for a +38% positive surprise, while Weibo WB surged past bottom-line estimates by +100% to +54 cents per share. NetEase NTES surpassed expectations by 3 cents per share to $2.07, and Vipshop VIPS beat by a penny to 57 cents. JD, Weibo and VIPS are all up in pre-market trading, while NTES is lower by -6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Deere & Company (DE) : Free Stock Analysis Report NetEase, Inc. (NTES) : Free Stock Analysis Report Vipshop Holdings Limited (VIPS) : Free Stock Analysis Report Weibo Corporation (WB) : Free Stock Analysis Report Inc. (JD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
